Robert Vonderheide, MDEnriched profile
Director, Abramson Cancer Center; John H. Glick, MD, Abramson Cancer Center's Director Professor; Vice Dean for Cancer Programs, Perelman School of Medicine; Vice President for Cancer Programs, University of Pennsylvania Health System · California University of Pennsylvania
Overview
Updated 14 Jul 2026
Robert H. Vonderheide, MD, is Director, Abramson Cancer Center at University of Pennsylvania, Perelman School of Medicine / Abramson Cancer Center. The public record shows 800 publications with 45,666 citations (h-index 99), centered on Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research, Immunotherapy and Immune Responses. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 4 companies, 9 NIH-funded awards (2001–2026).
- Most recent indexed publication: 2026 · JMIR formative research
- Top research focus: Cancer Immunotherapy and Biomarkers
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 4 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 28 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 196.
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse
Sponsor: Inovio Pharmaceuticals
InvestigatorPhase 1CompletedNCT02960594 - Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma
Sponsor: Abramson Cancer Center at Penn Medicine
InvestigatorPhase 1CompletedNCT02588443 - Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors
Sponsor: Abramson Cancer Center at Penn Medicine
InvestigatorPhase 1CompletedNCT02225002
Industry payments
Updated 14 Jul 2026
4 companies reported payments to CMS in program years 2022–2025. These are public disclosures, not judgments. The latest:
- Lilly USA, LLCProgram year20251 payment
- EMD Serono Research & Development Institute, Inc.Program year20241 payment
- E.R. Squibb & Sons, L.L.C.Program year20231 payment
NIH funding
Updated 14 Jul 2026
9 NIH research awards on record, funded 2001–2026 per NIH RePORTER. The latest:
- Changing the natural history of pancreatic ductal adenocarcinoma with cancer interception strategies
University of Pennsylvania
FY2026$658,033R01CA303474
Congress activity
Updated 14 Jul 2026
91 congress contributions (2005–2026) across AACR, ASCO, SABCS per OpenAlex. The most recent:
- Abstract LB406: Active RAS inhibition intercepts pancreas cancer in mice
AACR Annual Meeting
AACR2026Co-authorLate-breaking
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Influence of Tumor-Draining Lymph Nodes on Immunotherapy: Lymphadenectomy May Have Its Limits.
Clinical cancer research
2026 - KRAS Inhibitors in Pancreas Cancer: Facts and Hopes about the Immunotherapy We Have All Been Waiting for.
Clinical cancer research
2026 - Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma.
Science (New York, N.Y.)
2026
Most-cited worksby citation count (OpenAlex)
- 01Understanding the tumor immune microenvironment (TIME) for effective therapy6,057 citations2018
- 02
- 03
- 04EMT and Dissemination Precede Pancreatic Tumor Formation2,118 citations2012
- 05
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
12 South Pavilion, 3400 Civic Center Blvd, Philadelphia, PA 19104
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
- Internal Medicine residency
Massachusetts General Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗ - Medical Oncology fellowship
Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
Editorial & leadership rolesjournal and society appointments
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aacr.org ↗
Secondary affiliationsappointments beyond the home institution
- Basser Center for BRCA
University of Pennsylvania
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aacrjournals.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →parkerici.org ↗
- Center for Cellular Immunotherapies
Perelman School of Medicine (Vonderheide Lab)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
Media & interviewspress, podcasts and appearances
- NBC News feature on pancreatic cancer mRNA vaccine trial results
quoted discussing immunotherapy mechanism shift
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nbcnews.com ↗ - Guest
Moffitt Cancer Center's ImmunoVerse podcast, "From KRAS to CD40: Advancing Pancreatic Cancer Immunotherapy"
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - Q&A interview
"Robert Vonderheide on Immunotherapy Advances," Cancer Discovery (AACR journal)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacrjournals.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/robert-vonderheide-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/robert-vonderheide-990099355
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Robert-H-Vonderheide-39694462
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by otherswhere others cite or feature them
- Other
bcrf.org/blog/blog-2024-podcast-robert-vonderheide-bcrf
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcrf.org ↗ - Other
moffitt.org/about-moffitt/podcasts/immunoverse/from-kras-to-cd40
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - X / Twitter
x.com/PC3Innovation/status/2034691520272478326
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Van Cutsem, MD, PhD
Universitair Ziekenhuis Leuven
- 1,845
- publications
- 177
- h-index
- 14
- trials
Josep Tabernero, MD, PhD
Vall d'Hebron Institut de Recerca
- 2,704
- publications
- 148
- h-index
- 19
- trials
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
- 1,745
- publications
- 154
- h-index
- 22
- trials
Charles Fuchs, MD, MPH
Yale Cancer Center
- 1,721
- publications
- 172
- h-index
- 7
- trials